[Special Stock] BioSolution's 'KatiLife' Introduced in Overseas Journal for Domestic Phase 2 Clinical Trial... 'Rising'

[Asia Economy Reporter Minji Lee] BioSolution is on the rise following news that the results of the domestic Phase 2 clinical trial of Cartilife, a knee cartilage treatment, have been published in an international journal.

At 11 a.m. on the 3rd, BioSolution was trading at 28,050 KRW, up 7.47% from the previous session. On the same day, the company announced that the Phase 2 clinical trial results were published in 'Cartilage,' the official journal of the International Cartilage Regeneration Society, an overseas SCI journal. This journal is known for its credibility in the fields of cartilage regeneration, function, and degeneration.

Previously, Hongguk Jin, a researcher at Korea Investment & Securities, explained, “Through domestic and international clinical trials, BioSolution aims to designate Cartilife as a fundamental treatment that improves not only pain but also inflammation,” adding, “If the designation as a fundamental treatment becomes a reality, it could serve as a strong momentum for stock price growth.”